No-Site

Site Details

LOCATION

No Location

Site Trials

Hepatitis

Open and enrolling

A5394 - Seguridad, tolerabilidad e impacto del selgantolimod, agonista oral de TLR8, sobre el HBsAg (antígeno de superficie del virus de la Hepatitis B) en participantes con hepatitis B crónica y VIH

Tuberculosis

Closed to accrual

A5312: The Early Bactericidal Activity of High Dose or Standard Dose Isoniazid among adult Participants with Isoniazid-Resistant or Drug Sensitive Tuberculosis

This study is for participants who have pulmonary tuberculosis (TB), a bacterial infection in their lungs. Isoniazid (INH) is a drug commonly used to treat TB. Sometimes, the bacteria that cause TB can become resistant to INH, and then INH does not work as well at fighting the bacteria. This study will treat people with INH-resistant TB with different doses of INH to see if INH can still fight the bacteria if we just increase the dose.

Tuberculosis

Open and enrolling

A5356: A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination with a Short Course Regimen for the Treatment of Drug-Resistant Tuberculosis

Hepatitis

Open and enrolling

A5394: Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV

COVID-19 and Mpox

Closed to accrual

A5407 - Ensayo ambulatorio de fase 3 controlado con placebo del agente Shionogi para el tratamiento de la infección sintomática por SARS-CoV-2